Poseida Net Income Per Share from 2010 to 2025

PSTX Stock  USD 9.50  0.08  0.84%   
Poseida Therapeutics Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to -1.65 in 2025. During the period from 2010 to 2025, Poseida Therapeutics Net Loss regression line of annual values had r-squared of  0.41 and arithmetic mean of (0.62). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(1.57)
Current Value
(1.65)
Quarterly Volatility
0.77177548
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Poseida Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Poseida Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 10.5 M, Income Tax Expense of 101.1 K or Tax Provision of 129.2 K, as well as many indicators such as Price To Sales Ratio of 5.12, Dividend Yield of 0.0 or PTB Ratio of 4.84. Poseida financial statements analysis is a perfect complement when working with Poseida Therapeutics Valuation or Volatility modules.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Latest Poseida Therapeutics' Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of Poseida Therapeutics over the last few years. It is Poseida Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Poseida Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Slightly volatile
   Net Income Per Share   
       Timeline  

Poseida Net Income Per Share Regression Statistics

Arithmetic Mean(0.62)
Geometric Mean0.26
Coefficient Of Variation(124.21)
Mean Deviation0.66
Median(0.08)
Standard Deviation0.77
Sample Variance0.60
Range2.4023
R-Value(0.64)
Mean Square Error0.38
R-Squared0.41
Significance0.01
Slope(0.10)
Total Sum of Squares8.93

Poseida Net Income Per Share History

2025 -1.65
2024 -1.57
2023 -1.37
2022 -0.89
2021 0.0708
2020 0.0681
2019 -2.33

About Poseida Therapeutics Financial Statements

Poseida Therapeutics investors use historical fundamental indicators, such as Poseida Therapeutics' Net Income Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Poseida Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss(1.57)(1.65)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Poseida Stock Analysis

When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.